Trajan reports strong sales and profit growth across the group

Latest News

Analytical science and device company Trajan Group Holdings (ASX:TRJ) has reported its full-year results for the 2022 financial year with revenues up 40.5 per cent to $107.6 million.

The company said reported earnings of $12.5 million.

The company made four acquisitions during the year - Axel Semrau, Neoteryx, LEAP PAL Parts and Consumables, and Chromatography Research Supplies - which it said contributed $22.7 million to revenue and $2.1 million to earnings.

Trajan said its two business segments - Analytical Products and Life Science Solutions - reported improved revenue and earnings.

Revenue in the Analytical Products segment, which includes a range of analytical products focused on biological, food and environmental testing applications, rose 15 per cent to $60.3 million.

In the Life Science Solutions segment, which includes a range of automated workflow solutions along with products focused on areas directly related to human health, revenue was up 95.8% to $47.3 million.

Trajan provided revenue guidance for the financial year 2023 of between $150 million and $160 million and normalised earnings of $21-$25 million.

CEO Stephen Tomisich said, “Trajan continues to deliver on its plans and forecasts. The revenue and profit performance of the underlying business in both FY21 and now FY22 exceeded the guidance provided in the IPO Prospectus in early 2021. In FY22, post IPO, we did what we said we would do; deployed significant funds to bring forward our acquisition pipeline, completing four acquisitions in the first year since listing. Again, notably, those acquisitions now embedded in the Trajan Group are also performing to plan.

“We remain focused on our vision to deliver technologies that enable a future of personalised, preventative, data-based healthcare.”